Guggenheim Reiterates “Buy” Rating for Bruker (NASDAQ:BRKR)

Guggenheim reissued their buy rating on shares of Bruker (NASDAQ:BRKR) in a research note published on Friday,Benzinga reports.

BRKR has been the topic of a number of other reports. Bank of America raised their target price on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Citigroup decreased their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and an average price target of $74.45.

Bruker Stock Down 3.6 %

BRKR stock opened at $56.88 on Friday. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $8.62 billion, a P/E ratio of 27.35, a PEG ratio of 3.55 and a beta of 1.17. The firm has a 50 day simple moving average of $57.79 and a 200-day simple moving average of $61.66.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. During the same quarter last year, the business earned $0.74 earnings per share. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. On average, equities research analysts predict that Bruker will post 2.39 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s dividend payout ratio is presently 9.62%.

Insider Activity

In related news, CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 28.30% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

A number of large investors have recently bought and sold shares of BRKR. True Wealth Design LLC boosted its stake in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after purchasing an additional 510 shares in the last quarter. Eagle Bay Advisors LLC increased its holdings in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. increased its holdings in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bruker in the second quarter worth about $52,000. Finally, GAMMA Investing LLC increased its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after acquiring an additional 388 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.